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Multivalent agents containing 1-substituted 2,3,4-
trihydroxyphenyl moieties as novel synthetic
polyphenols directed against HIV-1†‡
Aida Flores,a María José Camarasa,a María Jesús Pérez-Pérez,a Ana San-Félix,a
Jan Balzarinib and Ernesto Quesada*a
The synthesis and the assessment of the anti-HIV activity of a set of molecules inspired by the multivalent
structures of some naturally-occurring polyphenols (tannins) are reported. Different multibranched
scaffolds have been derived from pentaerythritol as the central core which distribute spatially synthetic
polyphenolic subunits based on 1-substituted 2,3,4-trihydroxyphenyl moieties. A tetrapodal compound
(13b) bearing four N-(2,3,4-trihydroxyphenyl)amide groups, exhibits remarkable selective activity against
HIV-1 with EC50 values in the micromolar scale, in the same range as those reported for the most rep-
resentative anti-HIV tannins. Preliminary SAR studies emphasize the importance of the 1-substituted
2,3,4-trihydroxyphenyl moiety, the presence of an amide as the linker and the multivalent architecture of
these molecules, since the anti-HIV activity increases with the number of polyphenolic moieties. The data
support the interest in synthetic polyphenols and represent a promising starting point for further design
and development of selective HIV-1 inhibitors.
Introduction
Acquired Immune Deficiency Syndrome (AIDS) remains a
major global health concern due to its worldwide extension
and the high mortality rate still associated with this disease.1
Current antiretroviral therapy against Human Immunodefi-
ciency Virus (HIV), the etiological agent of AIDS, consists of 26
clinically approved drugs,2 which are administrated in combi-
nation in the so-called Highly Active Antiretroviral Therapy
(HAART).3 This chemotherapeutic arsenal targets different
critical stages of the infectious cycle of the virus and has con-
verted AIDS from a lethal disease into a chronic, controlled
condition.4
In spite of the positive effects of the HAART multidrug
regime, the emergence of resistance to all drugs currently in
clinical use as well as the appearance of side effects, particu-
larly after long-term treatment, are major hurdles in the fight
against the virus.5,6 Additionally, HAART does not eliminate
the persistence of latent long-term reservoirs of HIV.7 As a
result, novel strategies and alternative therapeutic agents
directed against HIV are still required.8
Polyphenols are a heterogeneous class of naturally-occurring
compounds, usually secondary metabolites isolated from higher
plants, which have been structurally characterised by the pres-
ence of polyhydroxy-aromatic moieties on their molecular frame-
works.9 Many polyphenols have been proposed as anti-HIV
therapeutics, exerting different modes of action, ranging from
virus entry, reverse transcription, integration and virus matur-
ing.10 Some of the most noticeable polyphenols described so
far as agents against HIV include catechins,11 theaflavins12
(considered lately as inexpensive and safe microbicide
candidates for the prevention of HIV sexual transmission13), or
quercetin,14 most of them found in various gallate forms.
Among them, the family of hydrolysable tannins has
attracted particularly strong interest due to its remarkable
activity against HIV. This heterogeneous group of polyphenols
usually comprises a common architecture based on a multi-
branched molecular core that spatially distributes several
galloyl or galloyl-derived subunits, attached to the central
scaffold through ester linkages.15 Among these natural pro-
ducts must be noted some structurally simplified polyphenols
such as 1,3,4,5-tetragalloylapiitol. This secondary plant meta-
bolite contains an acyclic polyhydroxylated hydrocarbon core
(D-apiitol) functionalised with four gallate moieties. This
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tannin exemplifies how a structurally simple polyol can act as
an efficient distributing scaffold for polyphenolic subunits
resulting in a molecule endowed with anti-HIV activity.16
The biological activities associated with polyphenols have
been mainly attributed to the presence of differently functiona-
lised polyhydroxy-aromatic moieties on their structures. In par-
ticular, galloyl subunits are structural motifs widely found in
natural polyphenols. The presence of these groups constitutes
an essential requisite for any bioactivity in most polyphenolic
natural products.17 Very noticeably, flavonols lacking galloyl
moieties do not provide effective protection against HIV-1
infection and the number and position of free phenol (–OH)
groups determine their biological properties.18
Galloyl residues provide polyphenols with efficient donor
and acceptor-functionalities for hydrogen bonding, which give
these compounds the potential to bind to proteins and nucleic
acids.19,20 Moreover, galloyl-containing polyphenols are
notable anti-oxidants. A large body of evidence indicates that
the oxidative environment facilitates viral replication21 and
that HIV infection is enhanced by free-radical damage.22 In
this sense, it has been suggested that gallate groups attenuate
AIDS progression due to their anti-oxidant properties23 which
weaken the effects of the infection and the ability of the virus
to infect new cells.24
As previously mentioned, a remarkable feature of the hydro-
lysable tannins is their multi-branched structure. Thus, several
subunits of the polyhydroxy-aromatic moieties (i.e. gallic acid)
are distributed profusely at the periphery of the scaffolds. This
architecture provides these compounds with a dense outer
array of repeated polyphenolic motifs (multivalency).25 Actu-
ally, the multivalent concept of molecular design is currently
starting to be successfully employed in anti-HIV drug dis-
covery.26,27 The combined above-mentioned factors (hydrogen
bonding ability, anti-oxidative effect and multivalent architec-
ture) allow the biological effect of polyphenols at different
levels.
Albeit their intimate mechanisms of action have not been
characterized in full detail, polyphenols have been proposed as
useful candidates, either alone or in combination with conven-
tional therapeutics, for the treatment and prevention of HIV-1
infection.10a However, naturally-occurring polyphenols are
obtained as mixtures of compounds extracted from their
natural sources. This is a significant drawback because in
many cases antiviral activities are due to complex mixtures of
substances (plant extracts) whose composition can only be
estimated while further isolation of the active components
from the extracts can turn out to be an elusive and difficult
task. As a consequence, the development of chemical pro-
cedures able to allow access to pure, controlled samples of
polyphenols is of great interest. Furthermore, naturally-occur-
ring polyphenols can motivate and inspire researchers to look
for novel synthetic compounds based on related architectures
and/or new structurally-modified polyphenolic moieties. Sur-
prisingly, and despite this interest, polyphenols have been
only rarely explored as inspirational motifs of new anti-HIV
agents. Moreover, synthetic polyphenols described to date are
analogues in which changes were focused on the nature of the
scaffolds that distribute spatially the most ubiquitous polyphe-
nolic moiety, the galloyl residue.28 Thus, the promising anti-
viral profile of natural polyphenols and the lack of previous
work on structurally-modified analogues of these compounds
prompted us to initiate a program pursuing the discovery of
multivalent compounds containing novel synthetic polypheno-
lic subunits.
In this sense, we recently described a tripodal receptor con-
taining a triethylbenzene scaffold attached by amide linkers to
2,3,4-trihydroxybenzoyl groups (a galloyl isomer). It was stated
that this moiety allowed the formation of an intramolecular
hydrogen bond between the bridged-amide function and the
ortho-phenolic substituent, thus rigidifying the structures com-
pared to galloyl-containing compounds (3,4,5-trihydroxyphenyl
isomer). This pre-organisation provided this compound with
selective recognition properties for mannose-based polysac-
charides, which opened attractive prospects for its potential in
anti-infective strategies, including enveloped viruses such as
HIV.29
Based on these precedents, we describe herein the synthesis
and biological evaluation against HIV of a series of com-
pounds inspired by the architecture of some hydrolysable
tannins (such as 1,2,4,5-tetragalloylapiitol) in which the natu-
rally-occurring galloyl group (3,4,5-trihydroxybenzoyl moiety)
has been replaced by a synthetic 2,3,4-trihydroxyphenyl
nucleus functionalised at position 1 with different linkers that
allow their attachment to suitable scaffolds (Fig. 1).
As scaffolds, a series of simple mono-, bi-, tri- and tetra-
podal molecules were used to explore the role of the number of
polyphenolic subunits grafted onto a given backbone (multi-
valency) in the biological activity. Thus, pentaerythritol was
proposed as a versatile molecule for construction of the four-
branched core.30 The gradual loss of branches of the pentaery-
thritol core allowed access to tripodal and bipodal scaffolds,
while simple linear hydrocarbon chains of different lengths
were used for the monopodal molecules. In addition, alkyl
chains (2 or 3 methylene groups) have been introduced as
spacers to separate the polyphenolic subunits from the central
core in order to provide to the scaffolds both flexibility and
elongated branches, avoiding steric hindrance. Amide bonds
are ubiquitous in nature and chemically stable,31 so they were
the first choice for the linking functionalities, but esters, carba-
mates, ureas or triazoles (all good hydrogen bond donor and
acceptor functionalities) were also used in order to evaluate
the role of the linker on the biological activity. Thus far, we
describe the synthesis and anti-HIV activity of this new family
of compounds designed as synthetic polyphenols.
Results and discussion
Synthesis
We prepared a first series of compounds in which the selected
2,3,4-trihydroxyphenyl moiety was linked to a polyacid scaffold
by amide linkages. With this purpose, 2,3,4-trihydroxy aniline (8)
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was prepared from the commercially available 2,3,4-trihydroxy-
benzoic acid (1) according to the pathway depicted in
Scheme 1. Perbenzylation of the starting material 1 (acetone,
K2CO3, heating),
32 followed by saponification of the benzyl
ester, gave free acid 333 in high yield. Conversion of the
benzoic acid 3 into its aniline analogue 7 was performed
Fig. 1 Architecture of the proposed synthetic tannins.
Scheme 1 Synthesis of amine 2,3,4-trihydroxybenzene nucleus 7 via Curtius rearrangement.
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following a three-step synthetic sequence. The first transform-
ation involved a Curtius reaction34 using diphenylphosphoryl-
azide (DPPA) as a mild azide-transfer reagent.35 In this reaction,
the corresponding acyl-azide derivative of 3 is formed and
rearranged in situ to give the intermediate isocyanate 4, which
was not isolated from the reaction medium. A subsequent one-
pot reaction of 4 with alcohols (BnOH, MeOH) produced the
corresponding benzyl (5) and methyl (6a) carbamates respect-
ively in high yield.36 Removal of the Cbz (BnOCO) group in 5
was successfully achieved using an excess of tetrabutyl-
ammonium fluoride (TBAF) to afford the free aniline derivative
7 (Scheme 1, method A).37 However, despite the satisfactory
overall yield of the conversion, the large excess of TBAF that
has to be used to drive the deprotection to completion and the
toxicity of this reagent made it difficult to scale up this trans-
formation. Alternatively, the methyl carbamate 6a was efficien-
tly deprotected by alkaline hydrolysis using KOH as reagent
giving 7 in 98% yield. This procedure (Scheme 1, method B)
performed on 6a proved simpler from a practical point of view,
higher yielding overall, easily scalable and inexpensive com-
pared to the TBAF procedure (which is carried out specifically
on the CBz-protected aniline 5).
Unfortunately, free aniline 7 proved to be unstable and
decomposition was observed even when it was stored under
controlled conditions (low temperature and inert atmosphere).
To solve this limitation, 7 was converted immediately after iso-
lation into its HCl salt 8. Hence, hydrochloride 8 was stable
and could be stored at room temperature for months without
apparent degradation.
Next, scaffolds 10–12 with 4, 3 and 2 branched carboxylic
acids, respectively, were synthesised following a two-step route
that involves firstly the conjugate addition of suitable polyols
A, B and C to olefins with electron-withdrawing substitutents
followed by the conversion of the terminal functionalities
(CO2tBu or CN) into the free acids carried out as specifically
required (Scheme 2). Thus, tetraacid 10 was synthesised from
the inexpensive, commercially available pentaerythritol (A),
which reacts readily with acrylonitrile in aqueous media gener-
ating tetranitrile intermediate 9 (72% yield), which was finally
hydrolysed providing the desired tetraacid 10 in 86% yield.38
Tripodal scaffold 11 was synthesised from the commercially
available triol B and tert-butyl acrylate in 73% yield.39 tert-
Butyl protecting groups were then straightforwardly removed
by treatment with TFA, affording triacid 11 in 72% yield.40
Finally, bidentate scaffold 12 was synthesised through a
similar two-step sequence involving conjugate addition of
commercially available diol C to acrylonitrile in 98% yield41
and subsequent acid hydrolysis of nitrile groups to the corres-
ponding free acids in 64% yield.
Multivalent benzyl-protected amides 13a–15a were prepared
by coupling of 8 and polyacid scaffolds 10–12 mediated by
PyBOP/Et3N in dichloromethane as depicted in Scheme 3.
Transformations proceeded at room temperature in 48 h, but
gentle heating at 60 °C led the reaction to completion in
shortened reaction times (overnight) and satisfactory yields.
Hydrogenolysis of all the benzyl-protected compounds
13a–15a (H2, 3.1 bar, 25 °C, catalytic Pd/C) afforded the free-
phenols 13b–15b in good yields. The choice of benzyl as pro-
tecting group for the phenol functionalities proved successful
as easy instrumental procedures and minimal work-up were
required to achieve the fully deprotected compounds at high
purity (≥95% HPLC).
Scheme 2 Synthesis of multipodal polyacid scaffolds 10–12.
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In order to evaluate the influence on the activity of the posi-
tion of the phenol groups on the aromatic ring, the 3,4,5-
isomer derivative of 13b, namely compound 17b, was obtained
(Scheme 4). This compound was synthesized similarly to 13b
in 47% overall yield after two steps. The first transformation
involves a PyBOP-mediated coupling of scaffold 10 and the
corresponding 3,4,5-benzyloxy aniline 16 followed by hydro-
genolysis of the benzyl groups in 17a to afford 17b. Additionally,
with the aim of analysing the role of the free amide proton on
the activity, the N-methyl derivative 18b was prepared in 41%
overall yield by reaction of 13a with methyl iodide followed by
removal of the benzyl groups in 18a by hydrogenation.
Next, to complete the amide series of compounds with
monopodal structures and to properly evaluate the effect of
branching on the scaffolds, compounds 19b–21b were pre-
pared. Thus, 8 was straightforwardly functionalised with acetic
anhydride in pyridine to afford acetate 19a. Ethyl (20a; short-
chained derivative) and palmitoyl (21a; long-chained deriva-
tive) monopodal amides were synthesized by reaction of 8 with
the corresponding acyl chlorides in order to additionally evalu-
ate the role of the amphiphilic character of these molecules.
Finally, hydrogenolysis of the benzyl groups of 19a–21a
afforded the monopodal free-phenols 19b–21b in satisfactory
yields (Scheme 5).
Preliminary biological evaluation of compounds 13b–21b
indicated that the tetrapodal compound 13b showed promis-
ing anti-HIV-1 activity (see biological evaluation section). We
then considered preparing the tetrapodal amide 23b in which
the linker is reversed (NHCO instead of CONH), compared to
13b, in order to evaluate the influence of this structural para-
meter on the activity (Scheme 6). Thus, coupling of the suit-
able tetraamine 22 (prepared as will be discussed later) with
the corresponding acid 3 afforded 23a, whose further deprotec-
tion yielded 23b in 69% yield.
We were encouraged to extend the study to new molecules
with modified linkers between the scaffold and the 2,3,4-tri-
hydroxyphenyl moieties. Thus, isocyanate 4 emerged as a key
intermediate that allowed its direct conversion into carbamate
(OCONH) and urea-linked (NHCONH) derivatives, obtained
straightforwardly by reaction of 4 with alcohols and amine-
containing cores, respectively (Schemes 9 and 10). For the syn-
thesis of these compounds, scaffolds 22 and 24–26 were pre-
pared as shown in Schemes 7 and 8.
Treatment of tetraacid 10 with HCl gas in methanol42 fol-
lowed by reduction of the in situ-generated methyl ester inter-
mediate with LiAlH4 afforded tetraol 24. This sequential
method proved more reliable than the direct reduction of the
tetraacid 10 with borane–THF complex as described.43 Tri- and
bipodal alcohols 2544 and 2645 were obtained similarly by
reduction of their corresponding methyl ester intermediates D
and E (Scheme 7).
Conversion of the polyol 24 into the tetraamine 22
(Scheme 8) was performed firstly via tetraazide intermediate
27, which was obtained by a tandem procedure involving a
Mitsunobu activation of the primary alcohols of 24 (DIAD,
PPh3) followed by an in situ reaction with diphenylphosphoryl-
azide (DPPA), acting as an azide-transfer reagent. This trans-
formation allows a simple and straightforward synthesis of
tetraazide 27 alternatively to the described procedure,46 which
involves previous activation of the alcohols as mesylates, iso-
lation and subsequent conversion into their azide derivatives
by reaction with sodium azide. Finally, 27 was reduced to the
Scheme 3 Synthesis of amide-linked tetra-, tri- and bipodal compounds 13–15.
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Scheme 5 Synthesis of monopodal amide-linked compounds 19–21.
Scheme 4 Synthesis of amide-linked tetrapodal compounds 17–18.
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tetraamine 22 in 63% yield by catalytic hydrogenation under
standard conditions. Alternatively, compound 22 could be
obtained directly from the tetranitrile 9 by hydrogenation at
high pressure (70 bar, 70 °C; Scheme 8). This reaction was per-
formed in a continuous-flow reactor using immobilized
Co-RANEY® as the catalyst, providing the tetraamine in a single
step and quantitative yield. This was finally the method of
choice to reach the tetravalent amine-containing scaffold 22.
Reaction of polyols 24–26 with 4, generated in situ by the
treatment of 3 with DPPA as previously mentioned, afforded
carbamates 28a–30a in reasonable yields (Scheme 9). Debenzy-
lation by hydrogenation of 28a–30a proceeded satisfactorily
affording free polyphenols 28b–30b. Carbamate-linked com-
pounds were completed with the monodentate methyl deriva-
tive 6b (the synthesis of this benzyl-protected derivative was
previously described) and the octyl derivative 31b in order to
evaluate the effect of the amphiphilic nature of the carbamate.
Regarding urea-linked derivatives, tetradentate amine 22
(Scheme 10) reacted very poorly with isocyanate 4. Thus, only
by forcing reaction conditions under microwave irradiation
(100 °C for 90 min) was it possible to isolate tetrapodal urea
32a, albeit with a poor 17% yield. Additionally, reaction of 4
with propylamine afforded monodentate compound 33a in
52% yield. Monodentate urea 33b containing free phenol
groups was successfully isolated in 99% yield after hydrogen-
ation. However, tetradentate urea 32b was not obtained pure
Scheme 6 Synthesis of tetrapodal amide 23b.
Scheme 7 Synthesis of tetrapodal, tripodal and bipodal polyol scaffolds 24–26.
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after removal of the benzyl protecting groups in 32a. In this
case, the material isolated after hydrogenolysis contained
several minor by-products. Attempts to purify this crude
product (reverse-phase chromatography, recrystallization,
exchange resins, etc.) failed to increase purity of this tetraden-
tate urea. Thus, exceptionally, compound 32b was evaluated
biologically against HIV with a purity of 82% (as determined
by HPLC).
As will be seen in the biological section, the data obtained
from the evaluation against HIV of the amide (13b–15b,
17b–21b) and carbamate (6b, 28b–31b) series clearly indicated
that the more 2,3,4-trihydroxyphenyl moieties on the periphery
Scheme 8 Synthesis of tetrapodal polyamine (22) and polyazide (27) scaffolds.
Scheme 9 Synthesis of carbamate-linked series from key isocyanate 4.
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of the molecules, the better the anti-HIV activity. Thus, our
next series of structural modifications were performed based
on these findings and we decided to focus only on the tetra-
podal compounds, while the monopodal derivatives were
obtained for comparative purposes.
Next, compounds with an ester as the linker were prepared
(Scheme 11). In this case, derivative 36 was the key intermedi-
ate. This compound was obtained in a three-step sequence by
reduction of 2 with lithium aluminium hydride under stan-
dard conditions (LiAlH4, THF) to afford benzyl alcohol 34 in
80% yield.47 Subsequent conversion of this alcohol into
its aldehyde derivative 35 was initially performed by using
pyridinium chlorochromate (PCC) as the oxidizing agent
(Scheme 11, method A) as described in the literature for the
isomeric 3,4,5-trimethoxy analogue of 34.48 However, this
transformation afforded, after chromatography, only moderate
yields (45%) of the desired aldehyde 35. Alternatively, a MnO2-
mediated oxidation (Scheme 11, method B) was assayed giving
aldehyde 35 in better yield (69%) and avoiding tedious chro-
matographic purifications. Finally, a Dakin-type reaction
(H2O2–HCO2H) converted the aromatic aldehyde 35 into its
phenol derivative 36 as described.49
Coupling of compound 36 with the tetra-acid scaffold 10
was achieved readily by Steglich reaction mediated by DCC
and a catalytic amount of DMAP to give tetradentate ester 37a
in 62% yield. A simple monodentate ester 38a was also
obtained for comparative purposes by treatment of 36 with
acetic anhydride in pyridine. Finally, removal of the benzyl
ethers in 37a and 38a was carried out by hydrogenolysis using
the standard protocol. Deprotected compound 38b undergoes
a phenomenon of intramolecular acyl migration between
vicinal phenols, producing spontaneously in the hydrogen-
ation medium a (2 : 1) mixture of 1-acetyl/2-acetyl isomers 38b/
38c as determined by 1H-NMR. Tetraester 37b did not exhibit
this spontaneous trend of transesterification between the
phenol groups, although all compounds 37b and 38b/38c
proved labile in solution, probably due to partial hydrolysis of
the ester moieties.
Finally, in order to explore new structural modifications on
the linker, we considered it of interest to replace the amide
bridge of the most active tetrapodal compound 13b by a non-
hydrolysable surrogate. The triazole group has been proposed
as a non-classical bioisostere of the amide moiety retaining
the main parameters of the original group (electronic pro-
perties, lipophilicity, size and geometry) while introducing
structural diversity. Additionally, triazole groups have the
advantages of a remarkable chemical stability and easy gene-
ration (click chemistry).50 Thus, two non-hydrolysable triazole-
linked tetrapodal agents 40b and 43b were synthesized as
shown in Scheme 12. Two different azide–alkyne pairs were
used. For the synthesis of 40b, acetylene 39 was required. Com-
pound 39 was obtained from the benzyl alcohol 34 through a
sequential one-pot oxidation–propargylation protocol.51 Thus,
34 was oxidised by activated MnO2 (THF, reflux) with no
Scheme 10 Synthesis of tetrapodal and monopodal urea-linked compounds from isocyanate 4.
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isolation of intermediate aldehyde 35, which was transformed
in situ into the corresponding acetylene 39 by treatment with
dimethyl-(1-diazo-2-oxopropyl)phosphonate (Bestmann–Ohira
reagent) in the presence of K2CO3 at room temperature.
52
Subsequently, Huisgen reaction (Cu(I)-catalysed [1,3]-dipolar
cycloaddition)53 between 39 and the previously mentioned
Scheme 12 Synthesis of tetrapodal triazole-linked polyphenols.
Scheme 11 Synthesis of monopodal and tetrapodal esters 37b and 38b/38c.
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tetraazide 27 in the presence of CuSO4 and sodium ascorbate
afforded tetra-triazole 40a in good yield (81%).
On the other hand, tetrapodal derivative 43a was obtained
by coupling of aryl-azide 41 and its acetylenic pentaerythritol
counterpart 42. Compound 41 was obtained from the hydro-
chloride 8, which was converted into its diazo derivative (not
isolated) by treatment with sodium nitrite and subsequently
substituted in situ by treatment with sodium azide to afford
41, although in low yield (23%; non-optimised procedure).
Huisgen coupling of 41 with 42 (synthesized by O-propargyl-
ation of pentaerythritol54) provided 43a in satisfactory yield
(60%). Finally, removal of benzyl protecting groups in both 40a
and 43a was carried out under standard conditions affording
deprotected polyphenols 40b and 43b in 60% and 85% yield,
respectively.
Biological assays. Antiviral activity
The new synthetic polyphenols were evaluated for their inhibi-
tory activity against HIV-1(IIIB) and HIV-2 (ROD) in a cell-
based assay (CD4
+ T-lymphocyte cell culture) where virus
infected cells were incubated in the presence of the selected
compounds.
It must be noted firstly that none of the benzyl-protected
polyphenols exhibited activity against HIV at subtoxic concen-
trations (data not shown), which clearly indicates that free
phenol functions are crucial for any antiviral activity in this
family of compounds. The results of the biological evaluation
of the deprotected compounds against HIV are summarized in
Table 1.
Whereas some of the described compounds inhibited
HIV-1 replication in the lower micromolar concentration
range, none of these derivatives proved active against HIV-2 at
sub-toxic concentrations (Table 1). Therefore, the active com-
pounds should be considered as specific inhibitors of HIV-1
replication in CD4+ T-lymphocyte cells.
With respect to the architecture of the tested compounds, it
was shown that the number of polyhydroxyphenyl moieties is
important for the activity. Thus, monopodal (6b, 19b–21b,
31b, 33b and 38b,c) and bipodal (15b and 30b) compounds
were all inactive against HIV replication at subtoxic concen-
trations. In the monopodal series of amides (19b–21b) and car-
bamates (6b and 31b), the length of the hydrocarbon side
chain (Me, Et, octyl and palmitoyl) linked to the phenolic
moiety did not affect their antiviral behaviour, indicating that
the hydrophobic character of the molecule has no significant
effect on activity. It should be noted additionally that com-
pound 21b, bearing a long palmitoyl hydrocarbon chain, has a
noticeably amphiphilic nature, which precluded its biological
testing at a higher concentration of 2 µM due to its limited
aqueous solubility.
Among the tripodal derivatives, only compound 14b exhibi-
ted a pronounced anti-HIV-1 activity (EC50 = 4.2 µM) although
its activity is 5-fold lower than its toxicity threshold (selectivity
index ∼6).
Regarding the tetrapodal series, compounds 40b and 43b,
with non-hydrolysable triazole linkers, and 37b and 32b, con-
nected to the scaffold with ester and urea linkers respectively,
were all inactive. In contrast, the tetrapodal amide-linked
Table 1 Anti HIV-1(IIIB) and anti-HIV-2(ROD) activity and cytostatic properties of the test compounds in human CD4
+ T-lymphocyte (CEM) cell
cultures
Linker Multiplicity Compound
EC50
a (µM)
CC50
b (µM)HIV-1 HIV-2
Carbamate Monopodal 6b >10 >10 171 ± 85
Amide Tetrapodal 13b 1.2 ± 0.6 ≥10 25 ± 11
Amide Tripodal 14b 4.2 ± 0.85 >10 24 ± 8.5
Amide Bipodal 15b >10 >10 60 ± 54
Amide (3,4,5-isomer) Tetrapodal 17b 5.6 ± 1.6 >10 21 ± 5.7
Amide (N-Me derivative) Tetrapodal 18b >10 >10 63 ± 37
Amide Monopodal 19b >50 >50 112 ± 0.0
Amide Monopodal 20b >50 >50 108 ± 2.1
Amide Monopodal 21b >2c >2c >2c
Amide (NHCOAr) Tetrapodal 23b 10 ± 0.0 >10 21 ± 2.8
Carbamate Tetrapodal 28b 8.4 ± 2.3 >10 20 ± 4.2
Carbamate Tripodal 29b >10 >10 24 ± 4.9
Carbamate Bipodal 30b >50 >50 86 ± 17
Carbamate Monopodal 31b >10 >10 124 ± 11
Urea Tetrapodal 32bd >10 >10 22 ± 0.0
Urea Monopodal 33b >50 >50 >250
Ester Tetrapodal 37b >50 >50 102 ± 21
Ester Monopodal 38b/38c >50 >50 >250
Triazole Tetrapodal 40b >10 >10 27 ± 2.8
Triazole Tetrapodal 43b >10 >10 48 ± 30
a 50% effective concentration or compound concentration required to protect 50% of the cells against the cytopathic effect of the virus. b 50%
cytostatic concentration or compound concentration required to inhibit CEM cell proliferation by 50%. All data are mean values (standard
deviation for at least three independent experiments). c Compound precipitation was detected at higher concentrations. d Product evaluated with
82% purity.
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derivative 13b was endowed with the highest antiviral activity
against HIV-1 (EC50 = 1.2 µM), a concentration markedly below
the toxicity threshold, resulting in a selectivity index of ∼20.
Very noticeably, reversion in the sequence of the amide linker
(NH–CO in 17b instead of CO–NH in 13b) caused a 4- to 5-fold
loss of antiviral activity (17b, EC50 = 5.6 µM) keeping similar
levels of cytostatic activity (CC50: 21 µM). Also, the tetrapodal
derivative 28b attached to the scaffold through a carbamate
group (NH–CO–O) was 7-fold less active than 13b (EC50 =
8.4 µM), linked by an amide (NHCO) moiety, but again, kept a
similar cytostatic potential as 13b and 17b. Overall, it can be
concluded that the best architecture is the tetrapodal configur-
ation and that, despite a common tetrapodal scaffold, the
linker group clearly affects the activity.
The amide series (compounds 13b–21b) can help to esta-
blish interesting structure–activity relationships. On the one
hand, the distribution of the free phenolic OH groups around
the aromatic ring is important for the biological activity. Thus,
compound 17b, bearing polyphenolic subunits with a galloyl-
type distribution (3,4,5-trihydroxyphenyl moieties), was 7-fold
less active (EC50 = 5.6 µM) than compound 13b, substituted by
the 2,3,4-trihydroxyphenyl isomer, showing that this moiety is
superior for this series of compounds. Moreover, compound
18b, in which amide NH groups have been eliminated by the
introduction of methyl groups, was inactive compared to 13b.
This indicates the importance of the free NH groups probably
to keep the capacity to form H-bridges with the molecular
target. Finally, compared to its less branched tripodal (14b),
bipodal (15b) and monopodal (19b–21b) analogs, the antiviral
profile of 13b indicates that at least four 2,3,4-trihydroxyphenyl
moieties located at the periphery of the molecule are required
for antiviral activity. These data support the importance of a
multi-branched architecture in the design of these families of
compounds. Moreover, it is interesting to notice that the cyto-
static activity of the antivirally active test compounds were
quite comparable, which opens promising future prospects of
further improvement of the selectivity index by optimizing
(increasing) the antiviral potency.
Conclusions
Herein we have described the synthesis and anti-HIV pro-
perties of a series of synthetic polyphenols containing a
central pentaerythritol-based core functionalised with 2,3,4-tri-
hydroxyphenyl subunits. Amide, carbamate, urea, ester and
triazole groups have been used as linkers to attach the poly-
phenolic moieties to the scaffolds. The design of these com-
pounds has been inspired by the multivalent architecture of
some representative naturally-occurring tannins. The effect of
the number of polyphenolic moieties has been studied by the
synthesis of a tetra-, tri- and bipodal series of compounds
while monopodal derivatives were obtained for comparative
purposes. Multibranched architecture seems to play a crucial
role in the design of these compounds, since the increase in
the number of peripheral polyphenolic subunits is associated
with an increased activity.
The tetrapodal amide-linked compound 13b is the most
active member of this series, exhibiting low micromolar inhibi-
tory activity against HIV-1, in the same range or even improved
compared to those values that have been reported for related
naturally-occurring polyphenols.10a The 2,3,4-trihydroxyphenyl
moiety present in these compounds proved superior to
the naturally-occurring gallate group (3,4,5-trihydroxybenzoyl
moiety). It is noteworthy that any structural changes per-
formed on the linker of the prototype amide-bridged com-
pound 13b led to a decrease in antiviral activity. The specific
molecular target of prototype compound 13b as well as its
exact mechanism of action are both still under investigation.
Furthermore, it must be noted that naturally-occurring poly-
phenols are extracts from natural sources whose composition
is variable, while the synthesis of the compounds described
herein has been carried out through a set of simple and
reliable transformations that allowed the isolation of pure,
controlled samples of the substances ready for biological
evaluation.
For all the above reasons, this contribution can be con-
sidered as an encouraging starting point for further develop-
ment of synthetic polyphenols as selective HIV-1 inhibitors.
Experimental
Chemical synthesis
General methods. Reactions were carried out with magnetic
stirring in round-bottomed flasks unless otherwise noted. Air
or moisture-sensitive reactions were conducted in oven-dried
glassware under a positive pressure of dry argon. Microwave-
mediated reactions were performed in a Biotage Initiator™ 2.0
reactor. Debenzylation of benzyl-protected phenols was per-
formed in a Parr-hydrogenator working at 3.1 bar and thermo-
stated at 25 °C. High-pressure hydrogenation of tetranitrile 9
was performed on an H-Cube® Continuous-flow Hydrogen-
ation reactor using Co-RANEY® as catalyst immobilized in a
CatCart®-Catalyst Cartridge System (both from Thales Nano).
All solvents were pre-dried, freshly distilled prior to use as
specifically described.55 Analytical thin layer chromatography
(TLC) was performed on pre-coated aluminum silica gel plates
60 (F254, 0.25 mm). Products were visualized from the TLC
under UV lamps (254 or 260 nm) or by heating after treatment
with developer solution (cerium ammonium molybdate (CAM),
phosphomolybdic acid (PMA) or vanillin). Separations were
performed on silica gel by preparative flash column chromato-
graphy56 or by Centrifugal Circular Thin-Layer Chromato-
graphy (CCTLC). Large scale purifications were conducted on
an automated flash purification system apparatus (Biotage
Isolera One). Oils or waxy solids were converted into foams by
repeated freeze-drying (lyophilization) from acetonitrile or
DMSO and traces of water for better handling of the products.
Mass spectra (low and high-resolution) were registered
with a quadrupole mass spectrometer Hewlett-Packard 1100
equipped with an electrospray source (ES) in negative or posi-
tive mode of detection. NMR spectra were obtained on Varian
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INOVA-300, -400, UNITY-500, MERCURY-400 or Bruker
AVANCE-300 NMR spectrometers using CDCl3 or methanol-d4
as solvents. 1H and 13C NMR spectra are reported in parts per
million (ppm) referred to protonated residual peaks or specific
signals due to deuterated solvents as internal references
in CDCl3 or CD3OD. The following abbreviations are used to
describe peaks: s (singlet), d (doublet), t (triplet), qt (quartet),
qn (quintet), m (multiplet) and br (broad).
HPLC analyses were carried out using either a Waters Alli-
ance HPLC/MS system (quoted as HPLC/MS) or on an Agilent
1120 apparatus (quoted as HPLC) eluting with acetonitrile–
water. All retention times are quoted in minutes. Elemental
analyses were performed with a Carlo Erba CHN-1108 or a
Heraeus CHN-O-RAPID microanalyzers. Melting points were
measured on a Mettler Toledo model MP70 melting point
apparatus and are uncorrected. Lyophilised compounds melt
at a wide range of temperatures.
A representative set of compounds are described in this
Experimental section. A detailed full description of all the
analytical methods, experimental procedures, spectroscopic
characterization and selected copies of 1H and 13C-NMR
spectra of intermediates and final compounds are provided
separately in the ESI‡ available.
Preparation of 2,3,4-tris(benzyloxy)aniline (7) from carbamate
precursors
Method A. Reaction with TBAF. Specific method for benzyl-
carbamate deprotection. Cbz-protected aniline 5 (1.1 g,
2 mmol) was dissolved in dry, freshly distilled THF (5 mL)
under argon atmosphere at room temperature. A solution of
TBAF in THF (1 M solution, 30 mL, 15 equiv.) was added and
the reaction mixture was heated at 60 °C overnight. TLC moni-
toring indicated complete deprotection of carbamate. Volatiles
were removed under vacuum and the residue embedded in a
pad of celite and directly purified by column chromatography
on SiO2 (hexane–EtOAc (2 : 1) v/v as eluent). Free amine 7 was
isolated as a waxy solid, converted into a white foam after
repeated freeze-drying from CH3CN–H2O (627 mg, 1.5 mmol,
76%). TLC (Rf = 0.32; hexane–EtOAc (3 : 2) v/v; CAM);
1H NMR
(400 MHz, CDCl3) δ: 7.45–7.3 (m, 15 H), 6.6 (d, J = 8.8 Hz, 1H),
6.49 (d, J = 8.8 Hz, 1H), 5.1 (s, 2H), 5.07 (s, 2H), 5.04 (s, 2H);
13C NMR (100 MHz, CDCl3) δ: 145.5, 143.4, 140.8, 137.9, 137.8,
137.7, 135.5, 128.6, 128.5, 128.4, 128.2, 128.0, 127.9, 127.8,
111.7, 110.1, 75.7, 75.2, 72.5; m/z (ESI+) 434 ([M + Na]+, 26%),
412 ([M + H]+, 100%); HPLC/MS: tR = 2.55 min. polar gradient
CH3CN–H2O from (70 : 30) up to (100 : 0) in 5 min (98%
purity).
Method B. Alkaline hydrolysis of carbamates. General pro-
cedure. A 40% solution of KOH in methanol (5 mL mmol−1)
was added to the methyl carbamate 6a (1 g, 1.83 mmol). The
slurry was stirred under reflux overnight (monitored by TLC).
Then, it was cooled to room temperature and the solvent was
halved, diluted with H2O (10 mL mmol
−1) and extracted with
EtOAc (3 × 10 mL mmol−1). Combined organic layers were
dried over anhydrous Na2SO4, filtered and concentrated under
vacuum to yield the desired free amine 7, which was triturated
from cold diethyl ether, dried and isolated as a yellowish solid,
which was used without further purification (736 mg,
1.79 mmol, 98%). Isolated compound 7 by this method B is
identical to that obtained by the method A.
Preparation of aniline hydrochlorides 8 and 16. General
procedure
The free amine was re-dissolved in Et2O and a 1 N solution of
HCl in Et2O was added dropwise until an abundant precipitate
was formed. The precipitate was filtered off, gently washed
with additional amounts of Et2O and then efficiently dried to
give a solid that did not need further purification. Hydrochlo-
rides 8 and 16 can be stored without noticeable degradation
for months if kept in a cool and dry place.
2,3,4-Tris(benzyloxy)aniline hydrochloride (8). Following the
general procedure, aniline 7 was converted into its hydrochlo-
ride 8, isolated as a pale brownish solid. Mp 174.9–176.2 °C;
1H NMR (400 MHz, CDCl3) δ: 10.0 (br s, 3 H), 7.5 (d, J = 4.2 Hz,
2 H), 7.4–7.2 (m, 11 H), 7.2 (br d, J = 9.4 Hz, 1 H), 7.1 (dd, J =
5.1, 1.6 Hz, 2 H), 6.6 (d, J = 9.0 Hz, 1 H), 5.3 (s, 2 H), 5.1 (s,
2 H), 5.0 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ: 152.8, 146.0,
142.2, 136.8, 136.6, 136.3, 128.7, 128.6, 128.3, 128.2, 127.9,
127.5, 118.9, 118.3, 109.3, 75.9, 75.6, 71.2; m/z (ESI+): 823 ([2M −
HCl + H]+, 30%), 413 ([M − HCl + 2H]+, 38%), 412 ([M − HCl +
H]+, 100%).
PyBOP-mediated synthesis of multivalent amides 13a–15a and
17a. General procedure
To a suspension of the suitable polyacid (1 mmol) in dry
CH2Cl2 (20 mL mmol
−1) at 0 °C (ice-bath) was added sequen-
tially PyBOP (1.2 equiv. per acid group) and Et3N (3.75 equiv.
per acid group) in a pressure tube. When the acid is solubil-
ized (approx. 5 min), aniline hydrochloride 8 (1.2 equiv. per
acid group) was added and the pressure tube sealed. The reac-
tion mixture was warmed to 60 °C and stirred overnight until
consumption of the starting material (TLC monitoring). Then,
reaction was cooled to room temperature, washed with a 10%
citric acid aqueous solution and then with a 10% NaHCO3
aqueous solution, dried over anhydrous Na2SO4, filtered and
concentrated under vacuum. The crude product was purified
as determined.
Tetrakis[5-oxo-5-[(2,3,4-tribenzyloxyphenyl)amino]-2-oxapentyl]-
methane (13a). A mixture of tetra-acid 1038 (21 mg,
0.050 mmol), hydrochloride 8 (108 mg, 0.240 mmol), PyBOP
(126 mg, 0.240 mmol) and Et3N (104 µL, 0.725 mmol) in
CH2Cl2 (1 mL) was treated as described in the general pro-
cedure (reaction proceeded at room temperature). The crude
product was purified by CCTLC (EtOAc–hexane 10–80%) to
afford 13a (58 mg, 0.029 mmol, 58%) as a yellowish waxy foam
after freeze-drying. TLC (Rf = 0.26 hexane–EtOAc (2 : 3) v/v;
CAM); 1H NMR (500 MHz, CDCl3) δ: 7.80 (br s, 4 H), 7.75 (d,
J = 9.3 Hz, 4 H), 7.41–7.27 (m, 60 H), 6.57 (d, J = 9.4 Hz, 4 H),
5.04 (s, 16 H), 5.01 (s, 8 H), 3.44 (t, J = 5.7 Hz, 8 H), 3.18 (s,
8 H), 2.26 (t, J = 5.7 Hz, 8 H); 13C NMR (125 MHz, CDCl3)
δ: 169.2, 149.2, 142.6, 141.5, 137.4, 137.0, 136.8, 128.7, 128.6,
128.5, 128.3, 128.0, 127.9, 127.5, 126.1, 115.7, 109.4, 76.1, 75.5,
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71.2, 69.2, 67.0, 45.0, 37.7; m/z (ESI+) 1000 ([1/2M + 2H]+,
100%); HRMS (ESI+) [M + H]+ C125H121N4O20 requires
1997.8574, found: 1997.8568; Anal. calcd for C125H120N4O20
(1996.3): C, 75.13; H, 6.05; N, 2.80; found: C, 74.93; H, 6.13;
N, 2.95%.
The synthesis of compounds 14a–15a and 17a was per-
formed similarly following the general procedure. For full
details, see ESI‡ available.
Preparation of carbamates 28a–31a and ureas 32a–33a by
Curtius rearrangement. General procedure
To a solution of the appropriate benzoic acid (1 equiv.) in
toluene (5 mL mmol−1) under argon was added DPPA
(1.1 equiv.) and Et3N (1.1 equiv.) at room temperature. The
mixture was heated at 75 °C until complete disappearance of
the starting material (as monitored by TLC), yielding the iso-
cyanate intermediate 4 (not isolated). Then, the corresponding
alcohols or amines were added (1.2 equiv. per isocyanate
group to be functionalised). The reaction was stirred addition-
ally at 75 °C overnight (monitored by TLC), cooled to room
temperature and subsequently washed with a 1 N aqueous
solution of HCl and then with a saturated aqueous solution of
NaHCO3, dried over Na2SO4, filtered and concentrated
under reduced pressure. The crude product was purified as
determined.
Methyl (2,3,4-tris(benzyloxy)phenyl)carbamate (6a). Accord-
ing to the general procedure, acid 333 (1.55 g, 3.5 mmol), DPPA
(830 µL, 4 mmol) and Et3N (540 µL, 4 mmol) in toluene
(18 mL) were reacted to form isocyanate intermediate 4, which
was treated with methanol (170 μL, 0.4 mmol). After work-up,
the crude mixture was purified by CCTLC (polar gradient on
elution using EtOAc–hexane from (5 : 95) up to (20 : 80)) and
further recrystallized from MeOH to yield 6a (1.22 g, 2.6 mmol,
74%) as a white solid. Mp 89.1–90.7; TLC (Rf = 0.34 hexane–
EtOAc (4 : 1) v/v; CAM); 1H NMR (400 MHz, CDCl3) δ: 7.7 (br d,
1 H), 7.4–7.3 (m, 15 H), 6.89 (br s, 1 H), 6.76 (d, J = 9.2 Hz,
1 H), 5.09 (s, 4 H), 5.08 (s, 2 H), 3.71 (s, 3 H); 13C NMR
(100 MHz, CDCl3) δ: 154.0, 148.4, 141.7, 137.3, 137.0,
136.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.5,
126.2, 113.4, 109.8, 75.8, 75.6, 71.4, 52.2; m/z (ESI+) 492
([M + Na]+, 59%), 470 ([M + H]+, 100%); Anal. calcd for
C29H27NO5 (469.5): C, 74.18; H, 5.80; N, 2.98; found: C, 74.27;
H, 6.02; N, 3.20%.
Tetrakis[5-((2,3,4-tribenzyloxyphenyl)carbamoyl)oxy-2-oxapentyl]-
methane (28a). Following the general procedure, a solution of
acid 333 (478 mg, 1.1 mmol), DPPA (0.26 mL, 1.2 mmol) and
Et3N (0.17 mL, 1.2 mmol) in toluene (5.4 mL) was reacted to
form the isocyanate intermediate 4, which was treated with
tetraol 24 (100 mg, 0.27 mmol) (stirred overnight at 75 °C after
addition of 24). Additional acid 3 (239 mg, 0.54 mmol), DPPA
(0.13 mL, 0.6 mmol) and Et3N (83 mL, 0.6 mmol) were needed
for the reaction to proceed to completion. After the usual
work-up, the crude material was purified by CCTLC (polar gra-
dient EtOAc–hexane from (10 : 90) up to (50 : 50)) to afford 28a
(100 mg, 0.05 mmol, 21%) as a yellowish oil. TLC (Rf =
0.4 hexane–EtOAc (2 : 3) v/v; CAM); 1H NMR (400 MHz, CDCl3)
δ: 7.66 (br s, 4 H), 7.42–7.29 (m, 60 H), 6.91 (br s, 4 H), 6.71
(d, J = 9.3 Hz, 4 H), 5.06 (s, 8 H), 5.05 (s, 8 H), 5.04 (s, 8 H),
4.16 (t, J = 6.4 Hz, 8 H), 3.47 (t, J = 6.3 Hz, 8 H), 3.42 (s, 8 H),
1.87 (qn, J = 6.3 Hz, 8 H); 13C NMR (100 MHz, CDCl3) δ: 153.5,
148.3, 141.8, 141.7, 137.4, 137.0, 136.9, 128.6, 128.5, 128.4,
128.3, 128.0, 127.9, 127.5, 126.3, 113.6, 109.8, 75.9, 75.5, 71.4,
69.7, 67.6, 62.4, 45.3, 29.2; HRMS (ESI+) [M + Na]+
C129H128N4O24Na requires 2139.8816, found: 2139.8811.
The synthesis of carbamates 29a–31a and ureas 32a–33a
was performed similarly following the general procedure. For
full experimental details, see ESI‡ available.
Preparation of 1,2,3-triazole-bridged compounds 40a and 43a
by copper-catalysed 1,3-dipolar azide–alkyne cycloaddition
(Huisgen reaction). General procedure
To a suspension of the corresponding azide (1 equiv. per
alkyne) and alkyne (1 equiv. per azide) in tBuOH–H2O (2 : 1)
v/v (64 mL mmol−1) at room temperature was added
(+)-sodium L-ascorbate (0.4 equiv.) and CuSO4 (0.04 equiv.).
The heterogeneous mixture was stirred at room temperature
overnight and then treated with H2O. The resulting solid was
filtered, washed with H2O and purified as determined.
Tetrakis[5-(4-(2,3,4-tribenzyloxyphenyl)-1H-1,2,3-triazol-1-yl)-
2-oxapentyl]methane (40a). A suspension of tetra-azide 27
(20 mg, 0.04 mmol), alkyne 39 (72 mg, 0.17 mmol), (+)-sodium
L-ascorbate (3 mg, 0.017 mmol) and CuSO4 (1 mg,
0.002 mmol) in tBuOH–H2O (2.8 mL) was treated as described
in the general procedure. The crude solid was purified by
CCTLC on silica gel (polar gradient on elution, EtOAc–hexane
from (40 : 60) up to (100 : 0) v/v) affording 40a (75 mg,
0.04 mmol, 81%) as a yellowish oil. TLC (Rf = 0.32 hexane–
EtOAc (3 : 7) v/v; PMA); 1H NMR (500 MHz, CDCl3) δ: 7.89 (d,
J = 8.8 Hz, 4 H), 7.74 (s, 4 H), 7.44–7.28 (m, 60 H), 6.84 (d, J =
8.9 Hz, 4 H), 5.10 (s, 8 H), 5.08 (s, 8 H), 5.03 (s, 8 H), 4.31 (t,
J = 7.0 Hz, 8 H), 3.35 (t, J = 5.7 Hz, 8 H), 3.33 (s, 8 H), 1.97 (qn,
J = 6.4 Hz, 8 H); 13C NMR (125 MHz, CDCl3) δ: 152.8, 149.9,
143.1, 141.8, 137.5, 137.4, 136.7, 128.6, 128.5, 128.3, 128.1,
128.0, 127.5, 122.5, 122.0, 118.4, 109.9, 75.6, 75.5, 70.9, 69.5,
67.6, 47.2, 45.4, 30.3; HRMS (ESI+) [M + H]+ C133H129N12O16
MH requires 2149.9650, found: 21.9644.
Tetrakis[3-(1-(2,3,4-tribenzyloxyphenyl)-1H-1,2,3-triazol-4-yl)-
2-oxapropyl]methane (43a). A suspension of tetra-alkyne 4254
(14 mg, 0.048 mmol), azide 41 (83 mg, 0.190 mmol),
(+)-sodium L-ascorbate (4 mg, 0.019 mmol) and CuSO4 (1 mg,
0.002 mmol) in tBuOH–H2O (3.0 mL) was treated as described
in the general procedure. Additional (+)-sodium L-ascorbate
(0.4 equiv.) and CuSO4 (0.04 equiv.) were added to ensure full
conversion of the reaction. The crude solid was purified by
CCTLC (EtOAc–hexane 20–100%) to afford 43a (57 mg,
0.028 mmol, 60%) as a yellowish solid. Mp 50.2–51.1 °C; TLC
(Rf = 0.30 hexane–EtOAc (3 : 7) v/v; PMA);
1H NMR (400 MHz,
CDCl3) δ: 7.78 (d, J = 2.7 Hz, 4 H), 7.43–7.30 (m, 32 H,)
7.30–7.25 (m, 10 H), 7.21 (dd, J = 9.0, 4.6 Hz, 4 H), 7.18–7.14
(m, 10 H), 7.05–6.98 (m, 8 H), 6.76 (d, J = 9.1 Hz, 4 H), 5.08 (s,
8 H), 5.06 (s, 8 H), 4.87 (s, 8 H), 4.54 (s, 8 H), 3.52 (s, 8 H);
13C NMR (125 MHz, CDCl3) δ: 153.8, 146.1, 145.0, 142.7, 137.2,
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136.4, 136.3, 128.8, 128.7, 128.5, 128.4, 128.3, 127.7, 125.6,
124.8, 120.5, 109.4, 76.4, 75.9, 71.3, 69.5, 65.2, 45.7; HRMS
(ESI+) [M + H]+ C125H113N12O16 requires 2037.8398, found:
2037.8392; Anal. calcd for C125H112N12O16 (2038.30): C, 73.66;
H, 5.54; N, 8.25; found: C, 73.58; H, 5.51; N, 8.19%.
Preparation of free polyphenols 6b, 13b–15b, 17b–21b, 23b,
28b–33b, 37–38b/38c, 40b and 43b. Deprotection of benzylated
phenols by catalytic hydrogenation. General procedure
A solution of the corresponding benzyl-protected precursors
(1 mmol) in a binary mixture of solvents THF–methanol (1 : 1)
v/v (100 mL) containing catalytic amounts of Pd (on charcoal;
10 wt%) was hydrogenated overnight in a Parr Hydrogenator at
3.1 bar in a thermostated vessel at 25 °C. The Pd catalyst was
removed by filtration through a Whatman® filter paper 42 and
the solvent was removed under reduced pressure to give the
corresponding deprotected free-phenolic derivatives as single
products which were treated as specified. All debenzylated
compounds should be kept at −20 °C and protected from
direct exposure to light.
Tetrakis[5-oxo-5-((2,3,4-trihydroxyphenyl)amino)-2-oxapentyl]-
methane (13b). A solution of 13a (50 mg, 0.025 mmol) in
THF–MeOH (2.5 mL) was treated as described in the general
procedure to afford 13b (24 mg, 0.026 mmol, quantitative
yield) as a yellowish foam after freeze-drying without further
purification. 1H NMR (400 MHz, CD3OD) δ: 6.70 (d, J = 8.6 Hz,
4 H), 6.32 (d, J = 9.0 Hz, 4 H), 3.59 (t, J = 5.7 Hz, 8 H), 3.42 (s,
8 H), 2.50 (t, J = 5.7 Hz, 8 H); 13C NMR (100 MHz, CD3OD)
δ: 173.7, 145.2, 140.0, 136.0, 120.4, 114.6, 108.1, 71.0, 68.7,
46.9, 38.2; m/z (ESI+) 917 ([M + H]+, 100%), 477 ([M/2 + NH4)]
+,
94%); HRMS (ESI+) [M + Na]+ C41H48N4NaO20 requires
939.2760, found: 939.2749; Anal. calcd for C41H48N4O20
(916.8): C, 53.71; H, 5.28; N, 6.11; found: C, 53.42; H, 5.58;
N, 6.31%; HPLC: tR = 2.86 min. polar gradient CH3CN–H2O
from (10 : 90) up to (100 : 0) in 5 min (96% purity).
The synthesis of compounds 6b, 14b–15b, 17b–21b, 23b,
28b–33b, 37b–38b/38c, 40b and 43b was performed similarly
following the general procedure. For full details, see ESI.‡
Antiviral activity
The methodology of the anti-HIV assays was as follows: human
CD4
+ T-lymphocyte CEM cells (∼3 × 105 cells mL−1) were
infected with 100 CCID50 of HIV-1(IIIB) or HIV-2(ROD) mL
−1
and seeded in 200 μL wells of a 96-well microtiter plate con-
taining appropriate dilutions of the test compounds. After
4 days of incubation at 37 °C, HIV-induced CEM giant cell for-
mation was examined microscopically. The 50% effective con-
centration (EC50) was defined as the compound concentration
required to inhibit virus-induced cytopathy by 50%. The 50%
cytostatic concentration (CC50) was defined as the compound
concentration required to inhibit CEM cell proliferation by
50% as counted by a Coulter counter.
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